Close
Achema middle east
swop processing & packaging

Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Amgen announced that it will present data from several key Nplate(R) (romiplostim) studies at the 52nd Annual Meeting and Exposition of the ASH, Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of Nplate in this setting, including the final efficacy and safety results from the largest and longest study of Nplate in adult chronic ITP. Amgen will also present data for other marketed products including Neulasta(R) (pegfilgrastim) and Aranesp(R) (darbepoetin alfa). Sean Harper, M.D., senior vice president, Global Development and Chief Medical Officer at Amgen, The complete results from a 5-year open-label extension study of Nplate in the adult chronic ITP setting show that Nplate increases and sustains platelet counts in these patients and that adverse event rates were consistent with those reported in previous studies. This is the largest and longest study of Nplate in this setting, and reinforces the potential of Nplate as a long-term treatment option.

Latest stories

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »